NP-10679

N/A

Report date: 2024/10/10 20:00:04
NME

Base Information

Drug NameNP-10679
Drug Alias NameNP-10679
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 antagonists
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsIschemic StrokeSubstance-Related DisordersPain, Postoperative +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeurop Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeyltx IncNeurop Inc
Active IndicationsN/A
Inactive IndicationsIschemic StrokeSubstance-Related DisordersPain, Postoperative +[4] 

Other Information

ATC CodeN/A
Related LinksN/A